Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

CT Open to Enrollment

Antenatal Anxiety and Dyadic Immune Risk (ADIR) Study

Almost 10 million children in the United States are affected by at least one allergic disease and the rates of allergy are rising. Prior public health research shows that children born to individuals who are anxious during pregnancy have higher rates of allergy, but the cause behind this occurrence is not known.

A Clinical Study of Aliya™ Pulsed Electric Fields (PEF) Delivered Prior to Standard of Care Treatment for Advanced Cancer

This study is being done to look at the safety of delivering pulsed electric fields (PEF) to tumor(s) in patients with metastatic cancer within the lungs requiring biopsy, or tumor(s) from stage IV non-small cell lung cancer (NSCLC) requiring biopsy, who have not previously had treatment for the tumor(s), who are not surgical candidates, and who are considered eligible for first-line standard-of-care (SOC) cancer therapy. 
   

A phase IIa randomized, double-blinded clinical trial of naproxen or aspirin for cancer immune interception in Lynch syndrome

This study aims to learn more about the effects of naproxen and aspirin on the normal colon in people with Lynch syndrome. By doing this study, the study team hopes to gather information on the safety and effectiveness of naproxen and/or aspirin for the use of cancer immune interception in Lynch syndrome. Naproxen or aspirin may help to prevent the development of cancerous cells in the colon.   
  

A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

This clinical trial is for adult participants who have advanced blood cancer that has been previously treated and is now unresponsive.
   
The purpose of this study is to learn more about the safety and effectiveness of using an investigational drug, NC525, in the treatment of blood cancer. An “Investigational” drug means it has not been approved for marketing by any health authority including the U.S. Food and Drug Administration (FDA).
   

A Phase 2b, multicenter, randomized, double-blind study of safety and efficacy of TAK-755 (rADAMTS13) with minimal to no plasma exchange (PEX) in the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP)

This clinical trial is for adult participants who have a diagnosis of immune-mediated thrombotic thrombocytopenic purpura (iTTP).
   
The purpose of this study is to find out if an investigational study drug called TAK-755 is effective in treating iTTP with and without the current standard-of-care (SoC) treatment, which is daily plasma exchange (PEX). The purpose is also to find out how safe TAK-755 is, what are the side effects that might be related to it, and how often do they occur.
   

Randomized Phase 2 Study of daunorubicin and cytarabine liposome + Pomalidomide versus daunorubicin and cytarabine liposome in Newly Diagnosed AML with MDS-Related Changes

This study is being done to identify if there is a safe, tolerable, and effective schedule of pomalidomide treatment when it is given in combination after induction therapy with daunorubicin and cytarabine liposome for acute myeloid leukemia (AML). Additionally, the study will evaluate if the combination of pomalidomide and daunorubicin and cytarabine liposome induction therapy is more effective in controlling AML than induction therapy with daunorubicin and cytarabine liposome alone.
   

A Phase 2 Study of Ipatasertib in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

This study is being done to evaluate if adding the drug ipatasertib to the usual approach is able to safely lower the chance of head and neck squamous cell cancer growing or spreading. This study aims to determine if this approach is better or worse than the usual approach.

The usual approach consists of treatment with immunotherapy using pembrolizumab. Pembrolizumab is approved by the U.S. Food and Drug Administration (FDA) and is administered through a vein in the arm.

Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with Both Chronic Hepatitis B and HIV

This study is evaluating the experimental drug selgantolimod (SLGN) for patients with Chronic Hepatitis B (CHB) to try to prevent progression and reverse disease. 

Experimental means that SLGN has not yet been approved by the U.S. Food and Drug Administration (FDA). 

An open label, single arm study of the safety and antiretroviral activity of the combination of 2 long-acting broadly neutralizing antibodies plus an IL-15 superagonist complex in ART-treated adults living with HIV during analytical treatment interruption

The purpose of this research study is to evaluate whether the 3 experimental study drugs being tested, 3BN117-LS, 10-1074-LS and N-803, are safe and tolerable for participants with HIV. Experimental means that these drugs have not yet been approved by the U.S. Food and Drug Administration (FDA). This study will also look at how well HIV is controlled after stopping antiretroviral therapy (ART).

A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease (STOMP)

The purpose of this study is to see if the drug tecovirimat helps people with mpox (formally known as monkeypox) heal faster. The study will also help us understand more about how human mpox causes disease and how the body fights off infection. 
   
Tecovirimat is approved by the U.S. Food and Drug Administration (FDA) for the treatment of smallpox and has been given safely to some people with mpox in the recent outbreak. It is considered investigational in this study as it has not yet been approved to treat mpox.